Allogene Therapeutics, Inc. (ALLO)
收市後：
Allogene Therapeutics, Inc.
210 East Grand Avenue
South San Francisco, CA 94080
United States
650 457 2700
https://www.allogene.com
版塊: Healthcare
行業: Biotechnology
全職員工: 232
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Arie S. Belldegrun F.A.C.S., M.D. | Co-Founder & Executive Chairman | 714.25k | 無 | 1949 |
| Dr. David D. Chang M.D., Ph.D. | Co-Founder, President, CEO & Director | 1.1M | 無 | 1960 |
| Mr. Joshua A. Kazam | Co-Founder & Director | 711k | 無 | 1977 |
| Mr. Geoffrey M. Parker | Executive VP & CFO | 無 | 無 | 1965 |
| Mr. Timothy L. Moore Ph.D. | Executive VP & Chief Technical Officer | 無 | 無 | 1961 |
| Mr. Earl M. Douglas Esq. | General Counsel & Compliance Officer | 無 | 無 | 1963 |
| Ms. Susan R. Lundeen | Chief People Officer | 無 | 無 | 1966 |
| Ms. Christine Cassiano | Executive VP, Chief Corporate Affairs & Brand Strategy Officer | 無 | 無 | 無 |
| Dr. Zachary J. Roberts M.D., Ph.D. | Executive VP of Research & Development and Chief Medical Officer | 無 | 無 | 1978 |
| Yinlin Chen | Senior Vice President of Finance | 無 | 無 | 無 |
描述
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
公司管治
截至 2024年4月1日 止，Allogene Therapeutics, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：5；董事會：9；股東權利：8；現金賠償：10。
